

Tsutomu Kobayashi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5076911/publications.pdf>

Version: 2024-02-01

84
papers

685
citations

623734

14
h-index

677142

22
g-index

87
all docs

87
docs citations

87
times ranked

1265
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e218-e225.	4.6	65
2	Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. <i>Cancer Science</i> , 2017, 108, 1007-1012.	3.9	55
3	Prognostic impact of a past or synchronous second cancer in diffuse large B cell lymphoma. <i>Blood Cancer Journal</i> , 2018, 8, 1.	6.2	51
4	Clinical features of immune-related thyroid dysfunction and its association with outcomes in patients with advanced malignancies treated by PD-1 blockade. <i>Oncology Letters</i> , 2019, 18, 2140-2147.	1.8	35
5	FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2013, 18, 1437-1446.	4.9	31
6	Phosphoinositide Protein Kinase PDPK1 Is a Crucial Cell Signaling Mediator in Multiple Myeloma. <i>Cancer Research</i> , 2014, 74, 7418-7429.	0.9	28
7	Lenalidomide and pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma. <i>British Journal of Haematology</i> , 2020, 191, 784-795.	2.5	28
8	Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2. <i>Investigational New Drugs</i> , 2019, 37, 210-222.	2.6	26
9	A Novel Diagnostic and Prognostic Biomarker Panel for Endothelial Cell Damage-Related Complications in Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1573-1581.	2.0	25
10	Epigenetic repression of miR-375 is the dominant mechanism for constitutive activation of the PDPK1/RPS6/KA3 signalling axis in multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 534-546.	2.5	24
11	Double-hit Lymphomas Constitute a Highly Aggressive Subgroup in Diffuse Large B-cell Lymphomas in the Era of Rituximab. <i>Japanese Journal of Clinical Oncology</i> , 2012, 42, 1035-1042.	1.3	18
12	Aberrant BUB1 Overexpression Promotes Mitotic Segregation Errors and Chromosomal Instability in Multiple Myeloma. <i>Cancers</i> , 2020, 12, 2206.	3.7	18
13	Bortezomib plus dexamethasone for relapsed or treatment refractory multiple myeloma: the collaborative study at six institutes in Kyoto and Osaka. <i>International Journal of Hematology</i> , 2010, 92, 579-586.	1.6	16
14	Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma. <i>International Journal of Hematology</i> , 2012, 95, 516-526.	1.6	15
15	High-risk follicular lymphomas harbour more somatic mutations including those in the AID-motif. <i>Scientific Reports</i> , 2017, 7, 14039.	3.3	13
16	Suppression of SERPINA1-albumin complex formation by galectin-3 overexpression leads to paracrine growth promotion of chronic myelogenous leukemia cells. <i>Leukemia Research</i> , 2014, 38, 103-108.	0.8	12
17	Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma. <i>International Journal of Hematology</i> , 2015, 101, 37-45.	1.6	10
18	RSK2Ser227 Is a Therapeutic Target of Myeloma Cells Regardless of Upstream Signalings.. <i>Blood</i> , 2012, 120, 2945-2945.	1.4	10

#	ARTICLE	IF	CITATIONS
19	Phosphoinositide-dependent protein kinase 1 is a potential novel therapeutic target in mantle cell lymphoma. <i>Experimental Hematology</i> , 2018, 59, 72-81.e2.	0.4	9
20	Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. <i>International Journal of Hematology</i> , 2018, 107, 83-91.	1.6	9
21	Immunosuppressive therapy with rabbit antithymocyte globulin therapy for acquired aplastic anemia: a multi-institutional retrospective study in Japanese adult patients. <i>International Journal of Hematology</i> , 2019, 109, 278-285.	1.6	9
22	Serine ²²⁷ in the N-terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma. <i>Cancer Medicine</i> , 2020, 9, 5185-5199.	2.8	8
23	Anti-Myeloma Activity of Modified Galectin-9 through JNK and p38 MAPK Pathways.. <i>Blood</i> , 2009, 114, 952-952.	1.4	8
24	Successful Treatment of Chemotherapy-Refractory Angioimmunoblastic T Cell Lymphoma with Cyclosporin A. <i>Acta Haematologica</i> , 2012, 127, 10-15.	1.4	7
25	Extranodal marginal zone lymphoma of the uterine cervix with concomitant copy number gains of the MALT1 and BCL2 genes: A case report. <i>Oncology Letters</i> , 2017, 13, 3641-3645.	1.8	7
26	Diffuse large B cell lymphoma with chromosomal translocation t(14;19)(q32;q13) occurring in IgG4-related disease. <i>Annals of Hematology</i> , 2019, 98, 1785-1787.	1.8	7
27	Transcriptional dysregulation of the deleted in colorectal carcinoma gene in multiple myeloma and monoclonal gammopathy of undetermined significance. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 788-795.	2.8	6
28	Human herpesvirus-6 pneumonitis in a patient with follicular lymphoma following immunochemotherapy with rituximab. <i>Infection and Drug Resistance</i> , 2018, Volume 11, 701-705.	2.7	6
29	Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study. <i>International Journal of Hematology</i> , 2019, 110, 77-85.	1.6	6
30	Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide+rituximab (R2) vs. rituximab+placebo in relapsed/refractory indolent non-Hodgkin lymphoma. <i>International Journal of Hematology</i> , 2020, 111, 409-416.	1.6	6
31	Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib-based therapies for relapsed/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients. <i>Cancer Reports</i> , 2022, 5, e1476.	1.4	6
32	Establishment and Characteristics of a Novel Mantle Cell Lymphoma-derived Cell Line and a Bendamustine-resistant Subline. <i>Cancer Genomics and Proteomics</i> , 2018, 15, 213-223.	2.0	6
33	Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 787-804.	2.4	5
34	The longitudinal analysis of large granular lymphocytosis in patients with Philadelphia chromosome-positive leukemia treated with dasatinib. <i>International Journal of Hematology</i> , 2015, 102, 426-433.	1.6	5
35	Chromosomal abnormality variation detected by G-banding is associated with prognosis of diffuse large B-cell lymphoma treated by R ² -CHOP-based therapy. <i>Cancer Medicine</i> , 2018, 7, 655-664.	2.8	5
36	Prediction of delayed platelet engraftment after autologous stem cell transplantation for B-cell non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 3434-3441.	1.3	5

#	ARTICLE	IF	CITATIONS
37	Epstein-Barr virus-associated lymphoproliferative disease during imatinib mesylate treatment for chronic myeloid leukemia. <i>Haematologica</i> , 2019, 104, e376-e379.	3.5	5
38	Sequential therapy of four cycles of bortezomib, melphalan, and prednisolone followed by continuous lenalidomide and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 137-145.	1.8	5
39	EWSR1 overexpression is a pro-oncogenic event in multiple myeloma. <i>International Journal of Hematology</i> , 2021, 113, 381-394.	1.6	5
40	Durable Remission of Chemotherapy-Refractory Myeloid Sarcoma by Azacitidine. <i>Tohoku Journal of Experimental Medicine</i> , 2021, 254, 101-105.	1.2	5
41	Clinical impacts of frailty, poor performance status, and advanced age in carfilzomib-containing treatment for relapsed/refractory multiple myeloma: post hoc investigation of the KOTOSG multicenter pilot prospective observational study. <i>International Journal of Hematology</i> , 2022, 115, 350-362.	1.6	5
42	The Response to Second-line Induction with Bortezomib and Dexamethasone is Predictive of Long-term Outcomes Prior to High-dose Chemotherapy with Autologous Stem Cell Transplantation for Multiple Myeloma. <i>Internal Medicine</i> , 2013, 52, 961-968.	0.7	4
43	Detection of chromosomal abnormalities by G-banding and prognostic impact in follicular lymphoma in the rituximab era. <i>International Journal of Hematology</i> , 2017, 105, 658-667.	1.6	4
44	A novel method of amplified fluorescent in situ hybridization for detection of chromosomal microdeletions in B cell lymphoma. <i>International Journal of Hematology</i> , 2019, 109, 593-602.	1.6	4
45	Phase II study of nivolumab in Japanese patients with relapsed or refractory Hodgkin lymphoma previously treated with brentuximab vedotin (ONO-4538-15): An interim analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, e19018-e19018.	1.6	4
46	Hematologic Malignancies (HM)-Screen-Japan 01: A Mutation Profiling Multicenter Study on Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 4457-4457.	1.4	4
47	NS-018, a selective JAK2 inhibitor, preferentially inhibits CFU-GM colony formation by bone marrow mononuclear cells from high-risk myelodysplastic syndrome patients. <i>Leukemia Research</i> , 2014, 38, 619-624.	0.8	3
48	Primary intraocular natural killer-cell lymphoma successfully treated using a multidisciplinary strategy. <i>Annals of Hematology</i> , 2019, 98, 2617-2619.	1.8	3
49	<p><p>Chronic Invasive Fungal Rhinosinusitis with Atypical Clinical Presentation in an Immunocompromised Patient<p>. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 3225-3232.	2.7	3
50	Tumor-specific transcript variants of cyclin D1 in mantle cell lymphoma and multiple myeloma with chromosome 11q13 abnormalities. <i>Experimental Hematology</i> , 2020, 84, 45-53.e1.	0.4	3
51	<p>Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib</p>. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 1017-1021.	2.7	3
52	Combination of Bone Marrow Biopsy and Flow Cytometric Analysis: The Prognostically Relevant Central Approach for Detecting Bone Marrow Invasion in Diffuse Large B-Cell Lymphoma. <i>Diagnostics</i> , 2021, 11, 1724.	2.6	3
53	Lymphoma during pregnancy in Japan: a multicenter retrospective cohort study. <i>International Journal of Hematology</i> , 2022, 115, 382.	1.6	3
54	Reduced-Intensity Allogeneic Stem Cell Transplantation for Co-Emergence of Chemotherapy-Refractory Follicular Lymphoma and Therapy-Related Myelodysplastic Syndrome. <i>Case Reports in Oncology</i> , 2014, 7, 188-194.	0.7	2

#	ARTICLE	IF	CITATIONS
55	Second primary malignancy after rituximab-containing immunochemotherapy for diffuse large B cell lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 3378-3386.	1.3	2
56	Hematopoietic stem cell transplantation for diffuse large B-cell lymphoma having 8q24/ MYC rearrangement in Japan. <i>Hematological Oncology</i> , 2021, 39, 66-74.	1.7	2
57	Successful management of acquired hemophilia A onset during pregnancy: A case report. <i>Journal of Obstetrics and Gynaecology Research</i> , 2021, 47, 4060-4066.	1.3	2
58	Interim Analysis of Hematologic Malignancies (HM)-Screen-Japan 01: A Mutation Profiling Multicenter Study of Patients with AML. <i>Blood</i> , 2020, 136, 2-3.	1.4	2
59	Toward further simplification of elotuzumab therapy by subcutaneous administration. <i>International Journal of Hematology</i> , 2020, 112, 427-428.	1.6	1
60	Iguratimod triggers the relapse of methotrexate-associated lymphoproliferative disorder. <i>Annals of Hematology</i> , 2021, 100, 2849-2850.	1.8	1
61	Gastric Myeloid Sarcoma Mimicking a Scirrhus Gastric Cancer. <i>Internal Medicine</i> , 2022, 61, 1231-1235.	0.7	1
62	Genomic Analysis Focusing on RUNX1-RUNX1T1 in Japanese Patients with AML: HM-Screen-Japan 01. <i>Blood</i> , 2021, 138, 4464-4464.	1.4	1
63	Clinical Significance of FLT3 Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01. <i>Blood</i> , 2021, 138, 2313-2313.	1.4	1
64	Pretreatment serum level of interleukin-6 predicts carfilzomib-induced hypertension in relapsed/refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2022, 63, 1678-1685.	1.3	1
65	Prognostic value of the Kyoto Prognostic Index in higher-risk diffuse large B-cell lymphomas treated by upfront autologous stem cell transplantation in JCOG0908 trial. <i>Japanese Journal of Clinical Oncology</i> , 2022, , .	1.3	1
66	Clinical Implication of the Effect of the Production of Neutralizing Antibodies Against SARS-Cov-2 for Chronic Immune Thrombocytopenia Flare-Up Associated with COVID-19 Infection: A Case Report and the Review of Literature. <i>Infection and Drug Resistance</i> , 0, Volume 15, 2723-2728.	2.7	1
67	Transient dermatomyositis complicated with interstitial pneumonia. <i>APLAR Journal of Rheumatology</i> , 2007, 10, 160-163.	0.2	0
68	Identification and Functional Significance of Novel Type of Structurally Aberrant Transcripts of DCC In B-Cell Malignancies.. <i>Blood</i> , 2010, 116, 3623-3623.	1.4	0
69	Galectin-9 Overcomes Various Types of Treatment Resistance through ATF-3/Noxa Pathway-Mediated Apoptosis In Chronic Myelogenous Leukemia. <i>Blood</i> , 2010, 116, 4930-4930.	1.4	0
70	Galectin-3 Is the Molecular Target for Overcoming Multidrug Resistance Due to the Cell Protection by Bone Marrow Leukemia Microenvironment in Chronic Myeloid Leukemia,. <i>Blood</i> , 2011, 118, 3746-3746.	1.4	0
71	Leukemia Microenvironment-Specific Galectin-3 Expression of Leukemic Cells Promotes Malignant Niche Formation and Bone Marrow Lodgment of Leukemic Cells in Chronic Myelogenous Leukemia. <i>Blood</i> , 2011, 118, 1678-1678.	1.4	0
72	Fingolimod (FTY720) Overcomes the Resistance to Tyrosine Kinase Inhibitors Via Dual Activation of BIM and BID in Chronic Myelogenous Leukemia. <i>Blood</i> , 2012, 120, 3744-3744.	1.4	0

#	ARTICLE	IF	CITATIONS
73	3-Phosphoinositide-Dependent Protein Kinase 1 (PDPK1) Is a Pivotal Cell Signaling Mediator in Multiple Myeloma. <i>Blood</i> , 2014, 124, 4728-4728.	1.4	0
74	Chromosomal Translocation (14;16)-Positive Multiple Myeloma Shows Negativity for CD56 Expression and Unfavorable Outcome Even in the Era of Novel Drugs. <i>Blood</i> , 2014, 124, 3349-3349.	1.4	0
75	More Somatic Mutations Including Those in the Aid-Motif with High-Risk, Histologically Non-Transformed Follicular Lymphomas. <i>Blood</i> , 2016, 128, 4116-4116.	1.4	0
76	The Abnormal Repression of Mir-375 Expression By Overlapping Epigenetic Dysregulations in Myelomas. <i>Blood</i> , 2016, 128, 4460-4460.	1.4	0
77	ONSET OF ACQUIRED HEMOPHILIA A DURING ORAL ANTICOAGULANT ADMINISTRATION - A CONCERN ABOUT DELAYED DIAGNOSIS. <i>Japanese Journal of Transfusion and Cell Therapy</i> , 2018, 64, 540-544.	0.2	0
78	A New Prediction System for Platelet Recovery after Autologous Stem Cell Transplantation in B-Cell Non-Hodgkin Lymphomas. <i>Blood</i> , 2018, 132, 2137-2137.	1.4	0
79	Properties and Distribution of IDH-1/2 Mutations in Acute Myeloid Leukemia By the Comprehensive Genomic Analysis. <i>Blood</i> , 2021, 138, 4447-4447.	1.4	0
80	Genomic Analysis of <i>NPM1</i> Mutation and <i>KMT2A</i> (<i>MLL</i>)-Rearrangement/Amplification in Japanese Patients with Acute Myeloid Leukemia: Hematologic Malignancies (HM)-Screen-Japan 01. <i>Blood</i> , 2021, 138, 4460-4460.	1.4	0
81	Genetic Features of AML with <i>MLL</i> -Rearrangement and <i>NPM1</i> Mutation: An Interim-Analysis of HM-Screen-Japan 01. <i>Blood</i> , 2020, 136, 35-36.	1.4	0
82	Genomic Analysis of <i>FLT3</i> Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01. <i>Blood</i> , 2020, 136, 32-34.	1.4	0
83	Patients with B-cell lymphoma receiving anti-CD20 monoclonal antibody-containing chemotherapies and seroreactive patterns in response to COVID-19 vaccination. <i>International Journal of Hematology</i> , 2022, , 1.	1.6	0
84	A case of peripheral T _H 1 cell lymphoma unspecified following lymphomatoid papulosis. <i>Skin Cancer</i> , 2022, 37, 58-64.	0.0	0